BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18666211)

  • 1. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.
    Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I;
    Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
    Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
    Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
    Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
    Suzuki M; Shigematsu H; Nakajima T; Kubo R; Motohashi S; Sekine Y; Shibuya K; Iizasa T; Hiroshima K; Nakatani Y; Gazdar AF; Fujisawa T
    Clin Cancer Res; 2007 Oct; 13(20):6087-92. PubMed ID: 17947472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
    Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
    Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
    Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2001 Jul; 7(7):1850-5. PubMed ID: 11448895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
    Suzuki M; Iizasa T; Nakajima T; Kubo R; Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
    Ann Surg Oncol; 2007 Sep; 14(9):2636-42. PubMed ID: 17602269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer.
    Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M
    Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
    Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
    Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCND1 messenger RNA expression is correlated with EGFR mutation status in lung cancer.
    Sasaki H; Okuda K; Endo K; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Clin Lung Cancer; 2007 Sep; 8(8):493-6. PubMed ID: 17922974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.